GlassScriptPhysician profile
James Robert Hager
NPI 1386617322
$4,461.97
in general payments reported to CMS, 2019-2025
35 companies · $650 in 2025
The $650 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $773 · 2021: $844 · 2022: $558 · 2023: $390 · 2024: $676 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,298.09 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $789.71 | 2021-2025 | |
| Lilly USA, LLC | $263.89 | 2019-2025 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $241.03 | 2020-2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $193.73 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $164.43 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $151.37 | 2021 | |
| Redhill Biopharma INC. | $113.06 | 2020-2021 | |
| Abbott Laboratories | $97.43 | 2021-2025 | Id Now Instrument |
| Glaxosmithkline, LLC. | $95.30 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.01 | 2019-2024 | Jardiance |
| Indivior INC. | $93.23 | 2019-2023 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $87.73 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $87.43 | 2023-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $82.17 | 2022-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $79.98 | 2023-2025 | Brixadi |
| Novartis Pharmaceuticals Corporation | $57.89 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.01 | 2024 | Relistor, Xifaxan |
| Vertex Pharmaceuticals Incorporated | $48.37 | 2025 | |
| Esperion Therapeutics, INC. | $45.92 | 2020-2021 | |
| Exact Sciences Corporation | $45.03 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $31.58 | 2020 | |
| Janssen Pharmaceuticals, INC | $31.15 | 2019 | |
| Allergan, INC. | $23.91 | 2020 | |
| Insulet Corporation | $23.51 | 2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $22.87 | 2024 | Gvoke Hypopen |
| Tris Pharma INC | $22.56 | 2025 | Dyanavel Xr |
| Orexo US, INC. | $22.34 | 2023 | Zubsolv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.02 | 2025 | Caplyta |
| Tonix Medicines, INC. | $15.88 | 2025 | Tonmya |
| Optinose US, INC. | $13.59 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.40 | 2022 | |
| Novo Nordisk INC | $13.40 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.53 | 2021 | |
| Genentech USA, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.